> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Edge Therapeutics Gets Fast Track for Hemorrhage Treatment
- URL: https://www.fdaweb.com/edge-therapeutics-gets-fast-track-for-hemorrhage-treatment/
- Published: 2016-05-13T12:00:00.000Z
- Updated: 2026-09-14T21:02:29.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135672

FDA has granted fast-track designation to Edge Therapeutics for its EG-1962 for treating aneurysmal subarachnoid hemorrhage (aSAH). The company describes it as a novel polymeric nimodipine microparticle containing nimodipine suspended in a diluent of sodium hyaluronate that uses the company’s Precisa development platform and that is designed to improve patient outcomes following aSAH. Edge has also received orphan drug designation for the EG-1962 and plans to begin enrolling this year in a Phase 3 multi-center trial, NEWTON 2, to evaluate its efficacy and safety versus the standard of care, oral nimodipine, in adults with aSAH.